Navigation Links
ATS statement regarding White House decision to delay new ozone standard
Date:9/2/2011

Today, the White House issued a press release stating they would not move to issue a final standard on ozone pollution. The American Thoracic strongly condemns this decision. "This is not change we believe in," said ATS President-Elect Monica Kraft, MD, professor of medicine and director of the Asthma, Allergy and Airway Center at Duke University.

Ozone, also known as smog, is known to endanger patients with asthma, COPD and other respiratory conditions. Scientific studies have consistently shown that ozone at the current EPA-approved levels leads to missed school days, more emergency room visits and hospitalizationsand even premature death.

"What President Obama has called a 'regulatory burden' is what we physicians call a protective health standard," noted Dr. Kraft.

A number of physician groups have called upon President Obama to issue a stricter ozone standard, including the American Medical Association, the American Academy of Pediatrics and the American Thoracic Society.

"President Obama's announcement today represents a big set back for the public's health," said Dr. Kraft. "The ATS urges the President to reconsider today's disappointing decision, and we plan to redouble our efforts to educate and advocate for cleaner air for the benefit of all U.S. citizens."


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
ATS statement regarding White House decision to delay new ozone standard
Source:Eurekalert

Page: 1

Related biology news :

1. Statement by the Egg Nutrition Center and American Egg Board on Diabetes Care study on egg consumption
2. Press statement on new CDC MRSA study from SHEA president
3. Statement by Sandy Andelman, co-author of Drought sensitivity of the Amazon Rainforest
4. Press statement on new CDC MMWR on Klebseilla pneumonia Carbapenemase-producing organisms
5. ADA releases updated position statement on functional foods
6. Joint statement by German science organizations on green genetic engineering
7. AMP releases statement on oversight of laboratory tests
8. Statement of ESHRE on the European Commission proposal of viral screening
9. A mission statement for science educators
10. IBIA Statement Regarding the Release of the National Research Council Report - Biometric Recognition: Challenges and Opportunities
11. ASN statement in support of US Dietary Guidelines for Americans 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOGĀ“s multi-biometrics system.   Continue Reading ... ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
(Date:3/22/2017)... March 22, 2017  Ascendis Pharma A/S (Nasdaq: ... TransCon technology to address significant unmet medical needs ... the full year ended December 31, 2016. ... our company as we broadened our pipeline and ... rare disease company with an initial focus on ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017 ... announced that it has eclipsed the 130 million covered ... Cross Blue Shield of Texas . ... stages, the Company continues to enjoy strong payor acceptance ... of its clinical programs and genetic counseling, its industry-leading ...
Breaking Biology Technology: